ins19 car-t cells
Leukemia, B-cell
Beijing Immunochina Medical Science & Technology Co., Ltd.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Leukemia, B-cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Dartmouth-Hitchcock Medical Center | Phase 4 | BBB |
Ibrutinib Loxo Oncology, Inc. | Phase 4 | BBB |
Busulphan Dartmouth-Hitchcock Medical Center | Phase 4 | BB |
Pirtobrutinib Loxo Oncology, Inc. | Phase 3 | BB |
cc-5013 University of Wisconsin, Madison | Phase 2 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →